Thursday 16 October, 2025
Introduction: The novel mycobacterial membrane protein large 3 (MmpL3) transporter inhibitor MPL-447 is being developed for tuberculosis (TB) treatment by…
Read morePoster: Methodology - Study Design
Design evaluation and optimisation in nonlinear mixed effects models with the R package PFIM
Thursday 16 October, 2025
Objectives: Nonlinear mixed effects models (NLMEMs) are widely used in model-based drug development to analyse longitudinal data. For optimising the…
Read moreDesign evaluation and optimisation in nonlinear mixed effects models with the R package PFIM 6.0
Thursday 16 October, 2025
Objectives: Nonlinear mixed effects models (NLMEMs) are widely used in model-based drug development to analyse longitudinal data. For optimising the…
Read moreSimulation-based evaluation of combined Likelihood Ratio Test (cLRT) and Multiple Comparison Procedure (MCP) approaches to identify a dose-response relationship in the oncology setting under different study design variables
Thursday 16 October, 2025
Background In oncology, the FDA requests for more rational derivation of optimal doses [1]. A first step to dose optimisation…
Read moreSimulating maximum tolerated dose-finding oncology trials using the InSilicoTrials cloud-based platform
Thursday 16 October, 2025
Introduction: In silico clinical trials are expected to play an increasingly important role in guiding the design of oncology phase I…
Read morePrediction of human pharmacokinetics of subcutaneously administered depot formulation using MBPK model
Thursday 16 October, 2025
Introduction: Subcutaneous depot formulations are increasingly being utilized, especially for the administration of biopharmaceuticals. However, the mechanism of drug release…
Read moreCreation of Pharmacometric Framework to Evaluate Clinical Trial Data on Predictive Biomarkers
Thursday 16 October, 2025
Objectives: The identification of biomarkers that can predict subjects to respond to a therapy is an important objective of what…
Read moreEvaluation of release techniques for nanocarriers on the basis of IVIVC-PBPK modeling
Thursday 16 October, 2025
Introduction: The drug release kinetics is one of the significant factors influencing the efficacy of nanocarriers. Often the in vitro…
Read moreHow to reduce the total number of samples in a bioequivalence study without impacting statistical power
Thursday 16 October, 2025
Introduction/Objectives: Bioequivalence (BE) or biosimilarity studies are typically conducted to compare two drugs or formulations and show their similarity [1,…
Read moreTapping into the potential of pharmacometrics in preclinical infection models: a low-hanging fruit or joined efforts needed?
Thursday 16 October, 2025
Introduction: In the development of alternative anti-infective combination therapies, preclinical in vivo infection studies are performed to characterise the PKPD…
Read more